Shots: Characterized by discomfort or pain in the chest, Angina develops when the heart does not receive adequate oxygen-rich blood PharmaShots' Disease of the Month report aims to familiarize the general population with conditions impacting communities worldwide. The report outlines disease characteristics, types, symptoms, diagnosis, treatments, epidemiology, market size, clinical trial analysis, patient advocacy groups (PAGs),…
Shots: Characterized by the thickening or hardening of arteries due to plaque buildup, atherosclerosis leads to complications like heart attack or stroke PharmaShots' Disease of the Month report aims to familiarize the general population with conditions impacting communities worldwide. The report outlines disease characteristics, types, symptoms, diagnosis, treatments, epidemiology, market size, clinical trial analysis, patient…
Active Ingredient: rivaroxaban Strength: 2.5 mg, 10 mg, 15 mg, and 20 mg Dosage Form: Tablets Mechanism of Action: Factor Xa inhibitors First Approval: US (1 Jul 2011), EU (30 Sep 2008) Revenue Analysis of Xarelto1 Xarelto has been an important driver of the revenue generated from the cardiovascular portfolio of Janssen. The blood thinner showed an increase of 4%…
Shots:Dr. Mason spoke about the key findings from their in vitro study demonstrating EPA + statins effects in reduced lipid oxidation, which were presented at the ACC 2022He also spoke about the study design of the REDUCE-IT trial and its importance in the approval of its candidate in metabolic and cardiovascular diseasesThe interview summarizes…
Active Ingredients: ApixabanStrength: 2.5 mg and 5 mgDosage Form: TabletMechanism of Action: Factor Xa inhibitorsFirst Approval: US (Dec 28, 2012), EU (May 18, 2011)Revenue1Eliquis is a leading novel oral anticoagulant of BMS. The revenue for BMS continued to grow due to Eliquis and other recently launched new products. BMS and Pfizer jointly develop and…

